Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 5/2011

01-05-2011 | Current Opinion

Strategies for Quantifying the Relationship between Medications and Suicidal Behaviour

What has been Learned?

Authors: Professor Robert D. Gibbons, J. John Mann

Published in: Drug Safety | Issue 5/2011

Login to get access

Abstract

In recent years there has been considerable concern that certain classes of drugs, for example antidepressants, may increase the risk of suicide. In this current opinion article, we examine the literature on methodological and statistical approaches to the design and analysis of suicidal event studies. Experimental, ecological and observational studies of the relationship between drugs and suicidal events (thoughts, attempts and completion) are discussed. Areas considered include analysis of spontaneous reporting system data, ecological trends in national and/or small area (e.g. county) suicide rates, meta-analyses of randomized clinical trials, and large-scale medical claims data. New statistical and experimental strategies for investigating possible associations between drugs and suicide are highlighted, and we suggest directions for future statistical/methodological research. To put this into context, we then review the most recent literature on the relationship between drugs (antidepressants, antiepileptics, varenicline, montelukast and antipsychotics) and suicidal events.
Overall, there appears to be little evidence that drugs increase the risk of suicide and related behaviour. Numerous lines of evidence in adults clearly demonstrate that inadequate treatment of depression (pharmacotherapy and/ or psychotherapy) is associated with increased risk of suicidal behaviour. In children, the results are less clear and further study is required to better delineate which children benefit from treatment and who may be at increased risk as a consequence of treatment. From a statistical and methodological perspective, the field of pharmacoepidemiology is a fertile area for statistical research, both in theory and in application. In general, methods have been adopted from other areas such as general epidemiology, despite the singular nature of many of the problems that are unique to drug safety in general, in particular the study of rare events. Finally, there is considerable debate concerning the communication of risk. For suicide, regulatory action has been taken largely on the basis of evidence suggesting increased risk of suicidal thoughts. However, suicidal thoughts are quite common, particularly among patients with depression, and may have little relationship to suicidal behaviour and/or completion.
Literature
1.
Goldsmith SK, Pellmar TC, Kleinman AM, et al. Reducing suicide: a national imperative. Washington, DC: The National Academies Press, 2002; 1–516
2.
Brown CH, Wyman PA, Brinales JM, et al. The role or randomized trials in testing interventions for the prevention of youth suicide. Int J Psychiatry 2007; 19: 617–31CrossRef
3.
Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207–10PubMed
4.
Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999; 60 Suppl. 2: 77–84PubMedCrossRef
5.
Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. J Am Med Assoc 2003; 290: 1467–73CrossRef
6.
Thies-Flechtner K, Muller-Oerlinghausen B, Seibert W, et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: data from a randomized prospective trial. Pharmacopsychiatry 1996; 29: 103–7PubMedCrossRef
7.
Tondo L, Jamison KR, Baldessarini RJ. Effect of lithium maintenance on suicidal behavior in major mood disorders. Ann N Y Acad Sci 1997; 836: 339–51PubMedCrossRef
8.
Tondo L, Baldessarini RJ, Hennen J, et al. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 1998; 59: 405–14PubMedCrossRef
9.
Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a metaanalysis. Acta Psychiatr Scand 2001; 104: 163–72PubMedCrossRef
10.
Bowden RJ, Turkington DA. Instrumental variables. Cambridge: Cambridge University Press, 1984
11.
Brodersen A, Licht RW, Vestergaard P, et al. Sixteen-year mortality in patients with affective disorder commenced on lithium. Br J Psychiatry 2000; 176: 429–33PubMedCrossRef
12.
Baldessarini RJ, Tondo L. Suicide risk and treatments for patients with bipolar disorder. J Am Med Assoc 2003; 290: 1517–9CrossRef
13.
Isacsson G, Bergman U, Rich CL. Epidemiological data suggest antidepressants reduce suicide risk among depressives. J Affect Disord 1996; 41: 1–8PubMedCrossRef
14.
15.
Ohberg A, Vuori E, Klaukka T, et al. Antidepressants and suicide mortality. J Affect Disord 1994; 50: 225–33CrossRef
16.
Rich CL. Relationship between antidepressant treatment and suicide [letter]. J Clin Psychiatry 1999; 60: 340PubMedCrossRef
17.
Rihmer Z, Rutz W, Pihlgren H, et al. Decreasing tendency of seasonality in suicide may indicate lowering rate of depressive suicides in the population. Psychiatry Res 1998; 81: 233–40PubMedCrossRef
18.
19.
Olfson M, Shaffer D, Marcus SC, et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60: 978–82PubMed
20.
Hall WD, Mant A, Mitchell PB, et al. Association between antidepressant prescribing and suicide in Australia, 1991–2000: trend analysis. BMJ 2003; 326: 1008–12PubMedCrossRef
21.
Barbui C, Campomori A, D’Avanzo B, et al. Antidepressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates. Soc Psychiatry Psychiatr Epidemiol 1999; 34: 152–6PubMedCrossRef
22.
Rutz W. Preventing suicide and premature death by education and treatment. J Affect Disord 2001; 62: 123–9PubMedCrossRef
23.
Grunebaum MF, Ellis SP, Li S, et al. Antidepressants and suicide risk in the United States, 1985–1999. J Clin Psychiatry 2004; 65(11): 1456–62PubMedCrossRef
24.
Isacsson G, Boëthius G, Bergman U. Low level of antidepressant prescription for people who later commit suicide: 15 years of experience from a population-based drug database in Sweden. Acta Psychiatr Scand 1992; 85: 444–8PubMedCrossRef
25.
Oquendo MA, Malone KM, Ellis SP, et al. Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior. Am J Psychiatry 1999; 156: 190–4PubMed
26.
Isometsä E, Henriksson M, Heikkinen M, et al. Suicide and the use of antidepressants: drug treatment of depression is inadequate [letter]. BMJ 1994; 308: 915PubMedCrossRef
27.
Henriksson S, Boethius G, Isacsson G. Suicides are seldom prescribed antidepressants: findings from a prospective prescription database in Jamtland county, Sweden, 1985–95. Acta Psychiatr Scand 2001; 103: 301–6PubMedCrossRef
28.
Blazer DG, Hybel CF, Simonsick EM, et al. Marked differences in antidepressant use by race in an elderly community sample: 1986–1996. Am J Psychiatry 2000; 157: 1089–94PubMedCrossRef
29.
Takahashi Y. Amidst a sharp increase of suicide: suicide in Japan. Tokyo: Kokoro no Kagaku (Nihon Hyoron-sha) 1999; 88: 2–10
30.
Nakagawa A, Grunebaum MF, Ellis SP, et al. Suicide and antidepressant prescription rates in Japan, 1999–2003. J Clin Psychiatry 2007; 68: 908–16PubMedCrossRef
31.
Helgason T, Tomasson H, Zoega T. Antidepressants and public health in Iceland: time series analysis of national data. Br J Psychiatry 2004; 184: 157–62PubMedCrossRef
32.
Gibbons R, Hur K, Bhaumik D, et al. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005; 62: 165–72PubMedCrossRef
33.
Gibbons R, Hur K, Bhaumik D, et al. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 2006; 163: 1898–904PubMedCrossRef
34.
35.
Brent DA, Perper JA, Goldstein CE, et al. Risk factors for adolescent suicide: a comparison of adolescent suicide victims with suicidal inpatients. Arch Gen Psychiatry 1988; 45(6): 581–8PubMedCrossRef
36.
37.
Leon AC, Marzuk PM, Tardiff K, et al. Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. J Clin Psychiatry 2004; 65: 915–8PubMedCrossRef
38.
Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. Acta Psychiatr Scand 2005; 111: 286–90PubMedCrossRef
39.
Gray D, Moskos M, Keller T. Utah Youth Suicide Study new findings. Presented at the Annual Meeting of the American Association of Suicidology; 2003 Apr 23–26; Santa Fe
40.
Anderson RN. Deaths: leading causes for 2000. National Vital Statistics Reports. Hyattsville (MD): National Center for Health Statistics 2002; 50(16): 1–48
41.
Grunbaum JA, Kann L, Kinchen SA, et al. Youth risk behavior surveillance: United States, 2001. MMWR Surveill Summ 2002; 51: 1–62PubMed
42.
Fombonne E, Wostear G, Cooper V, et al. The Maudsley long-term follow-up of child and adolescent depression; 2, suicidality, criminality and social dysfunction in adulthood. Br J Psychiatry 2001; 179: 218–23PubMedCrossRef
43.
Weissman MM, Wolk S, Goldstein RB, et al. Depressed adolescents grown up. J Am Med Assoc 1999; 281: 1707–13CrossRef
44.
Kovacs M, Goldston D, Gatsonis C. Suicidal behaviors and childhood-onset depressive disorders: a longitudinal investigation. J Am Acad Child Adolesc Psychiatry 1993; 32: 8–20PubMedCrossRef
45.
Rao U, Weissman MM, Martin JA, et al. Childhood depression and risk of suicide: a preliminary report of a longitudinal study. J Am Acad Child Adolesc Psychiatry 1993; 32: 21–7PubMedCrossRef
46.
Hazell P, O’Connell D, Heathcote D, et al. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002; (2): CD002317
47.
Treatment for Adolescents with Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. J Am Med Assoc 2004; 292: 807–20CrossRef
48.
Mann JJ, Emslie G, Baldessarini RJ, et al. ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 2005; 31: 473–92CrossRef
49.
Emslie GJ, Rush AJ, Weinberg WA. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031–7PubMedCrossRef
50.
Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment. JAMA 2007; 297: 1683–96PubMedCrossRef
51.
Gibbons R, Brown CH, Hur K, et al. Early evidence on the effects of the FDA black box warning on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164: 1356–63PubMedCrossRef
52.
Valuck RJ, Libby AM, Sills MR, et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 2004; 18: 1119–32PubMedCrossRef
53.
Simon GE, Savarino J, Operskalski B. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163: 41–7PubMedCrossRef
54.
Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults. Arch Gen Psychiatry 2006; 63: 865–72PubMedCrossRef
55.
Tiihonen J, Lönnqvist J, Wahlbeck K, et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006; 63: 1358–67PubMedCrossRef
56.
57.
De Leo D, Dwyer J, Firman D, et al. Trends in hanging and firearm suicide rates in Australia: substitution of method? Suicide Life Threat Behav 2003; 33: 151–64PubMedCrossRef
58.
DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System. Am Stat 1999; 53: 177–90
59.
DuMouchel W, Pregibon D. Empirical Bayes screening for multi-item association. Proceedings of the Seventh ACM SIGKDD International Conference on Knowledge Discovery and Data Mining; 2001 Aug 26–29; San Francisco (CA), 67–76
60.
Sonesson C, Bock D. A review and discussion of prospective statistical surveillance in public health. J Royal Stat Soc A 2003; 166: 5–21CrossRef
61.
Gibbons RD, Segawa E, Karabatsos G, et al. Mixed-effects Poisson regression analysis of adverse event reports: the relationship between antidepressants and suicide. Stat Med 2008; 27: 1814–33PubMedCrossRef
62.
Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63: 332–9PubMedCrossRef
63.
Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability; 1965 Jun 21–Juy 18; Berkeley (CA). Vol 1. Berkeley (CA): University of California Press, 1967: 221–33
64.
White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica 1980; 48: 817–30CrossRef
65.
White H. Maximum likelihood estimation of misspecified models. Econometrica 1982; 50: 1–25CrossRef
66.
Ludwig J, Marcotte D. Anti-depressants, suicide and drug regulation. J Policy Anal Manage 2005; 24: 249–72PubMedCrossRef
67.
Hedeker D, Gibbons RD. Longitudinal data analysis. New York: Wiley, 2006
68.
69.
Malzahn U, Bohning D, Holling H. Nonparametric estimation of heterogeneity variance for the standardized difference used in meta-analysis. Biometrika 2000; 87: 619–32CrossRef
70.
Sidik K, Jonkman JN. Simple heterogeneity variance estimation for meta-analysis. Appl Stat (J Royal Stat Soc, Series C) 2005; 54: 367–84CrossRef
71.
Sidik K, Jonkman JN. A comparison of heterogeneity variance estimators in combining results of studies. Stat Med 2007; 26: 1964–81PubMedCrossRef
72.
Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. Stat Med 1998; 17: 841–56PubMedCrossRef
73.
Mittlboeck M, Heinzl H. A simulation study comparing properties of heterogeneity measures in meta-analyses. Stat Med 2006; 25: 4321–33CrossRef
74.
Rosenbaum P, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41–50CrossRef
75.
Gibbons RD, Hur K, Brown CH, et al. The relationship between antiepileptics and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry 2009; 66: 1354–60PubMedCrossRef
76.
Gibbons RD, Amatya AK, Brown CH, et al. Post-approval drug safety surveillance. Ann Rev Pub Health. 2010; 31: 419–37CrossRef
77.
Rosenbaum PR. Differential effects and generic biases in observational studies. Biometrika 2006; 93: 573–86CrossRef
78.
Efron B. Logistic regression, survival analysis, and the Kaplan Meier curve. J Am Stat Assoc 1988; 83: 414–25CrossRef
79.
Gibbons RD, Duan N, Meltzer D, et al. Waiting for organ transplantation: results of an analysis by Institute of Medicine Committee. Biostatistics 2003; 4: 207–22PubMedCrossRef
80.
Posner K, Oquendo MA, Gould M, et al. Columbia classification algorithm of suicide assessment (C-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007; 164: 1035–43PubMedCrossRef
81.
Gibbons RD, Brown CH, Hur K, et al. The relationship between antidepressants and suicide: results of analysis of the Veterans Health Administration datasets. Am J Psychiatry 2007; 164: 1044–9PubMedCrossRef
82.
83.
Pamer CA, Hammad TA, Wu YT, et al. Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions. Pharmacoepidemiol Drug Saf 2010; 19: 158–74PubMedCrossRef
84.
Rosack J. New data show declines in antidepressant prescribing. Psychiatr News 2005; 40: 1–6
85.
Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 2007; 64: 466–72PubMedCrossRef
86.
Centers for Disease Control and Prevention. Suicide trends among youths and young adults aged 10–24 years United States, 1990–2004. Morbidity and Mortality Weekly Review 2007; 56: 905–8
87.
Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007; 164: 884–91PubMedCrossRef
88.
Libby AM, Orton H, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 2009; 66: 633–9PubMedCrossRef
89.
Wheeler BW, Gunnell D, Metcalfe C, et al. The population impact on incidence of suicide and non-fatal self harm of regulatory action against the use of selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological study. BMJ 2008; 336: 542–7PubMedCrossRef
90.
91.
Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290: 1467–73PubMedCrossRef
92.
Collins JC, McFarland BH. Divalproex, lithium, and suicide among Medicaid patients with bipolar disorder. J Affect Disorder 2008; 107: 23–8CrossRef
93.
Arana A, Wentworth CE, Ayuso-Mateos JL, et al. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 2010; 363: 542–51PubMedCrossRef
94.
Gibbons RD, Hur K, Brown CH, et al. Gabapentin and suicide attempts. Pharmacoepidemiol Drug Saf 2010; 19: 1241–7PubMedCrossRef
95.
Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010; 303: 1401–9PubMedCrossRef
96.
Marcus S. Using omitted variable bias to assess uncertainty in the estimation of an AIDS education treatment effect. J Ed Behav Stat 1997; 22: 193–201
97.
Olesen JB, Hansen PR, Erdal J, et al. Antiepileptic drugs and risk of suicide: a national study. Pharmacoepidemiol Drug Saf 2010; 19: 518–24PubMed
98.
VanCott AC, Cramer JA, Copeland LA, et al. Suicide-related behaviors in older patients with new anti-epileptic drug use: data from the VA hospital system. BMC Med 2010; 8: 1–7CrossRef
99.
Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol 2009; 44: 568–79PubMedCrossRef
100.
Holbrook JT, Harik-Khan R. Montelukast and emotional well-being as a marker for depression: results from 3 randomized, double-masked clinical trials. J Allergy Clin Immunol 2008; 122: 828–9PubMedCrossRef
101.
Jick H, Hagberg KW, Egger P. Rate of suicide in patients taking montelukast. Pharmacotherapy 2009; 29: 165–6PubMedCrossRef
102.
Goodwin RD, Eaton WW. Asthma, suicidal ideation, and suicide attempts: findings from the Baltimore epidemiologic catchment area follow-up. Am J Public Health 2005; 95: 717–22PubMedCrossRef
103.
104.
Hays JT, Ebert JO. Varenicline for tobacco dependence. N Engl JMed 2008; 359: 2018–24CrossRef
105.
Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behavior: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805PubMedCrossRef
106.
Hemmingsson T, Kriebel D. Smoking at age 18–20 and suicide during 26 years of follow-up: how can the association be explained? Int J Epidemiol 2003; 32: 1000–4PubMedCrossRef
107.
Miller M, Hemenway D, Rimm E. Cigarettes and suicide: a prospective study of 50 000 men. Am J Public Health 2000; 90: 768–73PubMedCrossRef
108.
Cahill K, Stead L, Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf 2009; 32: 119–35PubMedCrossRef
109.
Nides M, Oncken C, Gonzalez D, et al. Smoking cessation with varenicline, a selective a4b2 nicotinic receptor partial agonist. Arch Intern Med 2006; 166: 1561–8PubMedCrossRef
110.
Keating GM, Siddiqui MA. Varenicline: a review of its use as an aid to smoking cessation therapy. CNS Drugs 2006; 20: 945–60PubMedCrossRef
111.
Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an a4×2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006; 296(1): 56–63PubMedCrossRef
112.
Oncken C, Gonzalez D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist varenicline, for smoking cessation. Arch Intern Med 2006; 166: 1571–7PubMedCrossRef
113.
Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296: 64–71PubMedCrossRef
114.
Kasliwal R, Wilton LV, Shakir SAW. Safety and drug utilization profile of varenicline as used in general practice in England. Drug Saf 2009; 32: 499–507PubMedCrossRef
115.
Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia. Arch Gen Psychiatry 2003; 60: 82–91PubMedCrossRef
116.
Khan A, Khan SR, Leventhal RM, et al. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry 2001; 158: 1449–54PubMedCrossRef
117.
Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf 2003; 12: 423–4PubMedCrossRef
118.
Montgomery SA, Montgomery DB, Rani SJ, et al. Maintenance therapy in repeat suicidal behaviour: a placebo-controlled trial. Proceedings of the Xth International Congress for Suicide Prevention and Crisis Intervention; 1979 June 17–20; Ottawa (ON), 227–9
119.
Soloff PH, Lis JA, Kelly T, et al. Self-mutilation and suicidal behavior in borderline personality disorder. J Personal Disord 1994; 8: 257–67CrossRef
Metadata
Title
Strategies for Quantifying the Relationship between Medications and Suicidal Behaviour
What has been Learned?
Authors
Professor Robert D. Gibbons
J. John Mann
Publication date
01-05-2011
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 5/2011
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/11589350-000000000-00000

Other articles of this Issue 5/2011

Drug Safety 5/2011 Go to the issue

Original Research Article

Mortality Rates and Causes of Death in Children with Epilepsy Prescribed Antiepileptic Drugs

Review Article

Drug-Induced Lupus Erythematosus

Commentary

Getting Through the Quicksand of the Relationship between Drugs and Suicide

Original Research Article

Suspected Adverse Drug Reactions Reported For Children Worldwide

Original Research Article

How Patient Reporters Identify Adverse Drug Reactions

Meeting Report

Novel Approaches to Assessing Cardiac Safety —Proceedings of a Workshop